News and Publications

Publications

Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept

 

Jacobsen JPR, Oh A, Bangle R, et al. Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept. Neuropsychopharmacology. 2019;44(12):2082-2090.

 

This comprehensive study was designed to optimize translational fidelity, It reports that high-dose oral adjunctive 5-HTP slow-release in mice is safe and effective in amplifying brain serotonin neurotransmission beyond the SSRI effect, as assessed by behavioral, biochemical, and gene transcription measures.

 

Adjunctive 5-hydroxytryptophan slow-release for treatment-resistant depression: clinical and preclinical rationale

 

Jacobsen JPR, Krystal AD, Krishnan KRR, et al. Adjunctive 5-hydroxytryptophan slow-release for treatment-resistant depression: clinical and preclinical rationale. Trends Pharmacol Sci. 2016;37(11):933-944.

 

This paper reviews the multipronged clinical data supporting that adjunctive 5-HTP SR could treat depression patients responding inadequately to first-line SSRI/SNRI antidepressants. That clinical data relates to earlier 5-HTP clinical research as well as clinical research with serotonergic antidepressants and compounds more broadly. Key supportive preclinical data is reviewed as well.

 

SSRI augmentation by 5-hydroxytryptophan slow release: mouse pharmacodynamic proof of concept

 

Jacobsen JP, Rudder ML, Roberts W, et al. SSRI augmentation by 5-hydroxytryptophan slow release: mouse pharmacodynamic proof of concept. Neuropsychopharmacology. 2016;41(9):2324-2334.

 

This study reports that 5-HTP slow-release synergizes with chronic SSRI in elevating extracellular serotonin in mice. It further demonstrates, assessing across a variety of physiological and behavioral measures, that slow-release delivery dramatically improves the safety and tolerability of 5-HTP administration.